Current Illinois CancerCare Clinical Trials

Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Study Number: URCC 21038

Study Summary:
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.

Status: Open

Peoria, Bloomington, Galesburg, Pekin, Washington

Study Coordinator(s)
  • Navigator Courtney, 309-243-3660 cbrown@illinoiscancercare.com
  • Kelsey, 309-243-3618 kfay@illinoiscancercare.com
  • Erica, 309-243-3626 eraynor@illinoiscancercare.com

Study Link

« Search Again
WordPress PopUp Plugin